Should patients with prostate cancer without bone metastases receive sodium clodronate? Commentary

Nature Clinical Practice Urology

Volumn 4, Issue 11, 2007, Pages 584-585

  Saad, Fred ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ENDOTHELIN RECEPTOR ANTAGONIST; I KAPPA B; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BONE METASTASIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; MALE; MORBIDITY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; TREATMENT OUTCOME;

EID: 36248965107     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0911     Document Type: Short Survey

References (4)

1. Hortobagyi GN et al. (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335: 1785-1791
2. Kyle RA et al. (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25: 2464-2472
3. Dearnaley DP et al. (2003) A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 95: 1300-1311
4. Saad F et al. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458-1468